Christopher Eisenschenk, PH.D image

Christopher Eisenschenk, PH.D

Shareholder

Phone: 352-375-8100
Email: FCE@slepatents.com Email Me
Download vCard
Print PDF

Education

  • B.S. Agriculture
    University of Florida
  • Ph.D. Department of Microbiology and Cell Science
    University of Florida
  • J.D. cum laude
    University of Baltimore School of Law

Areas of Practice

  • U.S. and International Patent Procurement and Enforcement Strategy
  • U.S. and International Patent Prosecution
  • Patentability Opinions
  • Freedom-to-Operate, Validity and Infringement Opinions
  • Patent Appeals, Reexamination and Reissue

Technology Areas

  • Cell Biology
  • Immunology
  • Infectious Disease
  • Monoclonal Antibody Technology
  • Biotechnology
  • Chemical Technology
  • Pharmaceuticals/ Medicinal Chemistry
  • Agriculture/ Agricultural Biotechnology
  • Medical Devices

Prior Professional Experience

  • Supervisory Patent Examiner (SPE); USPTO: Biotechnology Groups
  • Patent Examiner; USPTO: Biotechnology Groups

Awards and Recognitions

  • Board Certified in Intellectual Property Law by The Florida Bar
  • Bronze Medal for Superior Federal Service

Language Capabilities

  • English
  • German

PROFESSIONAL MEMBERSHIPS & ACTIVITIES

  • Registered to Practice before the United States Patent and Trademark Office (USPTO)
  • The Florida Bar
  • Bar of the State of Maryland
  • Guest Lecturer, University of Florida Levin College of Law

SELECTED PUBLICATIONS

  • Mechanism of serum resistance among Brucella abortus isolates. (1999). Veterinary Microbiology, 68(3-4): 235-244.
  • Serum sensitivity of field isolates and laboratory strains of Brucella abortus. (1995). American Journal of Veterinary Research, 56(12): 1592-1598.
  • Purification of the ninth component of the bovine complement cascade. (1992). American Journal of Veterinary Research, 53(4): 435-439.

SELECTED PATENTS

  • 11,099,193: Methods for Diagnosing or Monitoring Muscular Dystrophies
  • 11,072,784: Esterases and Uses Thereof
  • 11,072,803: Hybrid Dual Recombinant AAV Vector Systems for Gene Therapy
  • 11,066,470: Humanized Antibodies with Increased Stability
  • 11,014,962: Method for Protein Purification
  • 10,968,281: Anti-LSP1 Antibody
  • 10,947,176: Antimalarial Compositions and Uses Thereof
  • 10,900,060: Method of Producing Terpenes or Terpenoids
  • 10,894,035: Use of Indole Compounds to Stimulate the Immune System
  • 10,889,640: Tau-Binding Antibodies
  • 10,888,440: Intraosseous Stent

Studied the pathogenicity of Gram-negative bacterial cells and the means by which bacterial cells evade the immune system of infected individuals